These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 22742854)

  • 1. Association between hypocretin-1 and amyloid-β42 cerebrospinal fluid levels in Alzheimer's disease and healthy controls.
    Slats D; Claassen JA; Lammers GJ; Melis RJ; Verbeek MM; Overeem S
    Curr Alzheimer Res; 2012 Dec; 9(10):1119-25. PubMed ID: 22742854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypocretin in cerebrospinal fluid is positively correlated with Tau and pTau.
    Deuschle M; Schilling C; Leweke FM; Enning F; Pollmächer T; Esselmann H; Wiltfang J; Frölich L; Heuser I
    Neurosci Lett; 2014 Feb; 561():41-5. PubMed ID: 24373987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Obstructive sleep apnea may induce orexinergic system and cerebral β-amyloid metabolism dysregulation: is it a further proof for Alzheimer's disease risk?
    Liguori C; Mercuri NB; Nuccetelli M; Izzi F; Cordella A; Bernardini S; Placidi F
    Sleep Med; 2019 Apr; 56():171-176. PubMed ID: 30799255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.
    Galasko D; Chang L; Motter R; Clark CM; Kaye J; Knopman D; Thomas R; Kholodenko D; Schenk D; Lieberburg I; Miller B; Green R; Basherad R; Kertiles L; Boss MA; Seubert P
    Arch Neurol; 1998 Jul; 55(7):937-45. PubMed ID: 9678311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypocretin (orexin) loss in Alzheimer's disease.
    Fronczek R; van Geest S; Frölich M; Overeem S; Roelandse FW; Lammers GJ; Swaab DF
    Neurobiol Aging; 2012 Aug; 33(8):1642-50. PubMed ID: 21546124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
    Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
    Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
    J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSF dynamics of orexin and β-amyloid
    Lozano-Tovar S; Nuccetelli M; Placidi F; Izzi F; Sancesario G; Bernardini S; Biagio Mercuri N; Liguori C
    Neurosci Lett; 2024 Aug; 837():137914. PubMed ID: 39032802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid melanin-concentrating hormone (MCH) and hypocretin-1 (HCRT-1, orexin-A) in Alzheimer's disease.
    Schmidt FM; Kratzsch J; Gertz HJ; Tittmann M; Jahn I; Pietsch UC; Kaisers UX; Thiery J; Hegerl U; Schönknecht P
    PLoS One; 2013; 8(5):e63136. PubMed ID: 23667582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia.
    Compta Y; Santamaria J; Ratti L; Tolosa E; Iranzo A; Muñoz E; Valldeoriola F; Casamitjana R; Ríos J; Marti MJ
    Brain; 2009 Dec; 132(Pt 12):3308-17. PubMed ID: 19858078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease.
    Tapiola T; Pirttilä T; Mehta PD; Alafuzofff I; Lehtovirta M; Soininen H
    Neurobiol Aging; 2000; 21(5):735-40. PubMed ID: 11016543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.
    Mehta PD; Pirttilä T; Mehta SP; Sersen EA; Aisen PS; Wisniewski HM
    Arch Neurol; 2000 Jan; 57(1):100-5. PubMed ID: 10634455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
    J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma Amyloid-β (Aβ42) Correlates with Cerebrospinal Fluid Aβ42 in Alzheimer's Disease.
    Teunissen CE; Chiu MJ; Yang CC; Yang SY; Scheltens P; Zetterberg H; Blennow K
    J Alzheimers Dis; 2018; 62(4):1857-1863. PubMed ID: 29614646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orexinergic system dysregulation, sleep impairment, and cognitive decline in Alzheimer disease.
    Liguori C; Romigi A; Nuccetelli M; Zannino S; Sancesario G; Martorana A; Albanese M; Mercuri NB; Izzi F; Bernardini S; Nitti A; Sancesario GM; Sica F; Marciani MG; Placidi F
    JAMA Neurol; 2014 Dec; 71(12):1498-505. PubMed ID: 25322206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers.
    Slats D; Claassen JA; Spies PE; Borm G; Besse KT; van Aalst W; Tseng J; Sjögren MJ; Olde Rikkert MG; Verbeek MM
    Neurobiol Aging; 2012 Apr; 33(4):831.e1-9. PubMed ID: 21880396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process.
    Gabelle A; Jaussent I; Hirtz C; Vialaret J; Navucet S; Grasselli C; Robert P; Lehmann S; Dauvilliers Y
    Neurobiol Aging; 2017 May; 53():59-66. PubMed ID: 28235679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reappraisal of Aβ40 and Aβ42 Peptides Measurements in Cerebrospinal Fluid of Patients with Alzheimer's Disease.
    Fiorini M; Bongianni M; Benedetti MD; Monaco S; Zanusso G
    J Alzheimers Dis; 2018; 66(1):219-227. PubMed ID: 30282368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.